# Cellebrite DI Ltd. (CLBT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Technology / Software. Price $11.45, market value $2.9 billion.

## Valuation
- **P/E (trailing): 49.8×** (5-yr avg 27.9×, 3-yr avg 58.2×). Cellebrite DI Ltd. trades at 49.8× trailing earnings, well above its own five-year average of 27.9×: investors are paying up relative to the company's past. The Technology median in the September 2026 study was 32.1×. Forward P/E is 17.5×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.14**. A PEG of 0.14 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 5.6×**. Each dollar of revenue is priced at 5.6×.
- **Price / book: 5.3×**. The shares trade at 5.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: 4.5%** (5-yr avg 3.2%). Free cash flow equals 4.5% of the market value, above its five-year average of 3.2%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.0%**. The inverse of the P/E: 2.0% of the price is earned each year.

## Profitability
- **Gross margin: 83.0%**. Cellebrite DI Ltd. keeps 83.0% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 10.9%**. 10.9% of revenue is left after running the business.
- **Net margin: 16.5%**. 16.5% of each dollar of sales reaches the bottom line.
- **Return on equity: 16.2%**. 16.2% on shareholders' equity is solid.
- **Return on assets: 6.3%**. Each dollar of assets produces 6.3% of profit.

## Growth
- **Revenue growth (1 yr): 18.6%** (3-yr 20.7%/yr, 5-yr 19.5%/yr). Revenue grew 18.6% over the last year, against 19.5% a year compounded over five years.
- **EPS growth (1 yr): 123.0%** (3-yr -19.3%/yr). Earnings per share rose 123.0%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 127.1%/yr**. Free cash flow has compounded at 127.1% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Current ratio: 1.56** (quick 1.56). Current assets cover the next year's liabilities 1.56 times.
- **Altman Z-score: 5.52**. A Z-score of 5.52 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Cellebrite DI Ltd. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): -30.1%** (YTD -36.5%, 3-mo -17.1%). The shares are down 30.1% over twelve months including dividends.
- **From 52-week high: -42.7%** (19.5% above the low). Trading 43% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 0.70** (volatility 62%). Beta of 0.70 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CLBT · Page: https://foliofundamentals.com/stocks/clbt

Not investment advice.